CYP2C9*11 变异对苯妥英和(S)-华法林药代动力学的影响
研究在150名埃塞俄比亚犹太健康受试者中单次给予300 mg苯妥英和20 mg华法林,发现CYP2C9*1/*11携带者较CYP2C9*1/*1携带者苯妥英代谢比降低50%和62.2%,(S)-华法林口服清除率降低52.6%,提示CYP2C9*11酶活性下降超过50%。
要点
- CYP2C9*11携带者苯妥英代谢比降低50%–62.2%。
- CYP2C9*11携带者(S)-华法林口服清除率降低52.6%。
- 非洲裔患者用窄治疗窗药物前应考虑CYP2C9*11基因检测。
核心结论
- CYP2C9*11编码的酶活性下降超过50%,程度类似CYP2C9*3(无功能等位基因)。
研究设计与样本
- 在150名埃塞俄比亚犹太健康非吸烟受试者中,间隔至少一周单次给予300 mg苯妥英和20 mg华法林。
- 以(S)-华法林口服清除率和苯妥英代谢比(PMR 24/12与PMR 24/24)作为CYP2C9活性标志物。
主要发现
- CYP2C9*1/*11携带者(n=13)较CYP2C9*1/*1携带者(n=127)PMR 24/12降低50%(FDR q<0.001)。
- CYP2C9*1/*11携带者较CYP2C9*1/*1携带者PMR 24/24降低62.2%(FDR q<0.001)。
- CYP2C9*1/*11携带者较CYP2C9*1/*1携带者(S)-华法林口服清除率降低52.6%(FDR q<0.001)。
临床怎么用
- 非洲裔患者处方苯妥英、华法林、非甾体抗炎药或西尼莫德等窄治疗窗药物前,应考虑CYP2C9*11基因分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cytochrome P450 2C9 (CYP2C9) is responsible for the oxidative metabolism of about 15% of commonly used drugs, some of which are characterized by a narrow therapeutic window. CYP2C9 is highly polymorphic, and over 60 alleles have been described. CYP2C9*2 and CYP2C9*3 are the most common polymorphisms among White patients and both are associated with decreased activity. The evidence concerning the functional importance of less frequent variant alleles is scarce. The objective of the current study was to characterize the in vivo activity of CYP2C9 among carriers of CYP2C9*11, one of the "African" alleles and the fourth most common CYP2C9 variant allele among White patients by using two prototype substrates, phenytoin and (S)-warfarin. Single 300-mg phenytoin and 20-mg warfarin doses were given to 150 healthy Ethiopian Jewish participants who were nonsmokers, at least one week apart. (S)-warfarin oral clearance and phenytoin metabolic ratio (PMR) derived from the ratio of 5-(4-hydroxyphenyl)-5-phenylhydantoin in 24-hour urine collection to plasma phenytoin 12 hours (PMR 24/12) or 24 hours (PMR 24/24) post dosing, were used as markers of CYP2C9 activity. PMR 24/12 and PMR 24/24 were reduced by 50% and 62.2%, respectively, among carriers of CYP2C9*1/*11 (n = 13) as compared with carriers of CYP2C9*1/*1 (n = 127) (false discovery rate (FDR) q < 0.001). The respective decrease in (S)-warfarin oral clearance was 52.6% (FDR q < 0.001). In conclusion, the enzyme encoded by CYP2C9*11 is characterized by a more than 50% decrease in the enzymatic activity, resembling the extent of decrease associated with CYP2C9*3 ("no-function allele"). Among patients of African ancestry, CYP2C9*11 genetic analysis should be considered prior to prescribing of narrow therapeutic window drugs such as phenytoin, warfarin, nonsteroidal anti-inflammatory drugs, or siponimod.
引用
- Wanounou M, Shaul C, Abu Ghosh Z, et al. The Impact of CYP2C9*11 Allelic Variant on the Pharmacokinetics of Phenytoin and (S)-Warfarin. Clin Pharmacol Ther. 2022. PMID: 35426132. doi:10.1002/cpt.2613
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。